Global detection and management of dysglycaemic patients with coronary artery disease results from the INTERASPIRE survey from 14 countries across six WHO regions.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Al-Azzawy Safi Moayad, McEvoy John William, Johansson Isabelle, Adamska Agnieszka, De Backer Guy, Erlund Iris, Ganly Sandra, Jennings Catriona, Kotseva Kornelia, Lip Gregory Y H, Mellbin Linda, Ray Kausik K, Vihervaara Terhi, Wood David, Abreu Ana, Almahmeed Wael, Ambari Ade Meidian, Ge Junbo, Hasan-Ali Hosam, Huo Yong, Jankowski Piotr, Jimenez Rodney M, Li Yong, Zuhdi Syadi Mahmood, Makubi Abel, Mbakwem Amam Chinyere, Mbau Lilian, Estrada Jose Luis Navarro, Ogah Okechukwu Samuel, Ogola Elijah Nyainda, Quintero-Baiz Adalberto, Sani Mahmoud Umar, Liprandi Maria Ines Sosa, Tan Jack Wei Chieh, Triana Miguel Alberto Urina, Yeo Tee Joo, De Bacquer Dirk, Rydén Lars
Аннотация
METHODS: A total of 4,548 CAD patients (18-80 years) were interviewed 6 months-2 years after hospital admission. All without diabetes were eligible for an oral glucose test (OGTT).
RESULTS: Overall, 1990 (44%) had known T2DM. The OGTT revealed that 808 (40%) had previously unknown dysglycaemia (T2DM 12% and IGT 28%). Two thirds of all dysglycaemic patients were obese. A similar proportion reported low physical activity and only one third received dietary advice. Only half of dysglycemic patients were prescribed all guideline recommended cardioprotective drugs. A majority did not reach recommended blood pressure, lipids or HbA1c targets. Only 16% had attended a diabetes education program.
CONCLUSIONS: The INTERASPIRE study shows that screening for glucose perturbations in coronary patients is inadequate, achievement of lifestyle recommendations suboptimal and pharmacological management insufficient resulting in a poor risk factor control. Patients with coronary disease, especially those with glucose perturbations require professional support to achieve healthier lifestyles, and prescription of all cardioprotective medications to achieve guideline targets.